Key Takeaways
- • Chemed Corp (CHE) is trading at $417.85 per share as of April 20, 2026, down 28.1% from its 52-week high of $581.51, presenting a valuation opportunity for institutional investors evaluating entry points.
- • Q1 2026 revenue reached $657.5 million, up 1.63% year-over-year, with strong operational performance in the VITAS hospice segment driving analyst confidence in forward guidance increases.
- • Four to six analysts maintain a consensus "Buy" rating with average 12-month price targets ranging from $455.43 to $501.50, implying 4.84% to 20% upside from current levels over the next year.
- • Management repurchased 500,000 shares in Q1 2026 and raised full-year guidance, supported by VITAS segment strength and acquisition of two Roto-Rooter franchises, signaling confidence in operational momentum.
- • Stock remains down 22.5% over the trailing 12-month period despite strong long-term profitability metrics, creating a potential disconnect between valuation and fundamental performance that warrants reassessment.
Summary
Chemed Corporation (CHE) is trading near multi-month lows as of April 20, 2026, at $417.85 per share—a significant 28.1% decline from its 52-week high of $581.51. The stock is down 22.5% over the past year and has underperformed modestly by 1.4% since the beginning of 2026, though it remains 14.2% above its 52-week low of $365.21. The current pullback has created a valuation inflection point that institutional investors are reassessing relative to underlying operational performance.
Q1 2026 earnings results demonstrated mixed execution. Revenue grew to $657.5 million, representing modest 1.63% year-over-year growth that slightly exceeded consensus estimates. The VITAS hospice services segment emerged as the primary growth driver, delivering the operational strength that prompted management to increase full-year guidance. Additionally, Chemed repurchased 500,000 shares during the quarter and completed the acquisition of two Roto-Rooter franchises, both signals of capital allocation discipline and confidence in near-term prospects.
Analyst sentiment remains constructively aligned despite the recent drawdown. Four to six analysts covering the stock maintain a consensus "Buy" rating, with average 12-month price targets of $501.50 according to multiple sources, or $455.43 according to supplemental consensus data. This implies upside potential ranging from approximately 5% to 20% from current levels, though analyst commentary acknowledges the stock's recent earnings miss in Q4 that triggered a 15% single-day decline. The disconnect between strong long-term profitability metrics and recent price weakness suggests the market may be repricing near-term growth assumptions rather than fundamental deterioration.
The bull case hinges on sustained VITAS momentum and operational leverage from ongoing capital deployment. Management's decision to raise guidance despite near-term revenue growth moderation indicates confidence that the VITAS segment and franchise expansion can deliver accelerating results in subsequent quarters. For sophisticated investors evaluating CHE, the primary risk/reward calculation centers on whether VITAS growth can reignite above mid-single-digit trajectory, justifying analyst price targets that imply meaningful mean reversion from depressed valuations.
Q1 2026 earnings results demonstrated mixed execution. Revenue grew to $657.5 million, representing modest 1.63% year-over-year growth that slightly exceeded consensus estimates. The VITAS hospice services segment emerged as the primary growth driver, delivering the operational strength that prompted management to increase full-year guidance. Additionally, Chemed repurchased 500,000 shares during the quarter and completed the acquisition of two Roto-Rooter franchises, both signals of capital allocation discipline and confidence in near-term prospects.
Analyst sentiment remains constructively aligned despite the recent drawdown. Four to six analysts covering the stock maintain a consensus "Buy" rating, with average 12-month price targets of $501.50 according to multiple sources, or $455.43 according to supplemental consensus data. This implies upside potential ranging from approximately 5% to 20% from current levels, though analyst commentary acknowledges the stock's recent earnings miss in Q4 that triggered a 15% single-day decline. The disconnect between strong long-term profitability metrics and recent price weakness suggests the market may be repricing near-term growth assumptions rather than fundamental deterioration.
The bull case hinges on sustained VITAS momentum and operational leverage from ongoing capital deployment. Management's decision to raise guidance despite near-term revenue growth moderation indicates confidence that the VITAS segment and franchise expansion can deliver accelerating results in subsequent quarters. For sophisticated investors evaluating CHE, the primary risk/reward calculation centers on whether VITAS growth can reignite above mid-single-digit trajectory, justifying analyst price targets that imply meaningful mean reversion from depressed valuations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.